Klaus Schmierer

multiple sclerosis disease modifying treatment progressive multiple sclerosis neurology cladribine equity ms natalizumab primary progressive multiple sclerosis multiple sclerosis therapy neda neuroscience lower and middle income countries nhs neuroanatomy #chariotms #thinkhand upper limb function access to treatment b cells fingolimod rebound disease mri neuronal loss cerebral cortex spinal cord synapses axonal loss neuropathology post mortem immune therapy side effects adverse effects health scam social media treatment venoplasty ccsvi off-label health economics time matters #ectrims2016 spms disease progression ppms pml tysabri laquinimod arpeggio disease trials